Dr. Rebbaa received his PhD from Claude Bernard University, Lyon, France. He held research and faculty positions at Northwestern University, the University of Pittsburgh and Columbia University.  Over the course of his career, his research encompassed target and drug discovery and development in the fields of cancer, stem cells and aging. He served as a Principal Investigator on multiple grants, published over 40 manuscripts and reviewed manuscripts for several high impact scientific journals.

In his recent role at Ichor Therapeutics, he oversaw the discovery and preclinical testing of small molecule senolytics and biomarkers of aging. He will build on this knowledge and experience to take over an innovative project at the RepleniSENS program to study the effect of a combination therapy using senolytics and stem cell transplantation on reducing the functional decline caused by aging. He will also be using various in vitro and in vivo models to help advance translation of promising anti-aging therapeutics discovered at SRF.